GlassScriptPhysician profile
Stacey M Ritz
NPI 1649230624
$3,313.26
in general payments reported to CMS, 2019-2025
16 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $110 · 2021: $318 · 2022: $182 · 2023: $254 · 2024: $1,271 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557 · Education: $3.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,557.17 |
| Education | $3.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $574.43 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $493.06 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $411.13 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Oyster Point Pharma, INC. | $347.61 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $276.30 | 2019-2024 | Cequa |
| Dompe US, INC. | $246.31 | 2024-2025 | Oxervate |
| Alcon Vision LLC | $227.46 | 2022-2025 | Tryptyr, Eysuvis, Rocklatan |
| Novartis Pharmaceuticals Corporation | $215.54 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $163.72 | 2021 | |
| Biotissue Holdings INC. | $91.12 | 2024-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $80.97 | 2019-2021 | |
| Amgen INC. | $73.61 | 2024-2025 | Tepezza |
| Shire North American Group INC | $40.80 | 2019 | |
| Allergan, INC. | $36.30 | 2020-2021 | |
| Sight Sciences, INC. | $22.11 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $12.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Ritz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.